Implantica's RefluxStop® Gains Enthusiasm From Experts
Implantica AG, a pioneering medtech company, is making waves in the medical community with its innovative RefluxStop® device, designed for the treatment of acid reflux. This condition affects over a billion individuals globally, and the excitement surrounding RefluxStop® is growing as the device nears potential FDA approval.
Recently, at the annual meeting of the American Foregut Society (AFS), which attracted more than 600 medical professionals, RefluxStop® was a hot topic of discussion. Despite the impending U.S. launch, top foregut surgeons and gastroenterologists were eager to learn more about this groundbreaking treatment. Independent presentations by leading surgeons emphasized the new technology's promise, and a packed educational panel discussion drew nearly 120 experts eager to engage in dialogue about RefluxStop®.
The growing anticipation for RefluxStop® reflects a significant shift as surgical interest surges not only in the U.S. but also worldwide. As the third module of the PMA application approaches its conclusion, Implantica is proactively building the necessary infrastructure to facilitate a rapid and effective market entry once approval is secured.
Dr. John Lipham, Chief of the Division of Upper GI and General Surgery at USC, moderated the lively RefluxStop® panel discussion. His enthusiasm for the device was evident as he shared insights into its unique mechanism of action and long-term clinical outcomes. These discussions highlighted how RefluxStop® operates without encircling the esophagus, significantly minimizing associated complications.
Dr. Lipham stated, "I am very excited for RefluxStop as it comes closer to receiving FDA approval, given the impressive 5-year clinical study results consistent with real-world data from Europe. The way it treats GERD is an innovative approach that aligns with the latest scientific principles of the Anti-Reflux Barrier (ARB) endorsed by the American Foregut Society." He emphasized that the AFS's ARB approach addresses the overall anatomy of the body's natural anti-reflux mechanism, which RefluxStop® supports in a non-invasive manner.
In addition to Dr. Lipham, the panel featured experts such as Dr. Peter Kahrilas from Northwestern University and Dr. Tripp Buckley from the University of Texas at Austin. Together, they discussed the implications of RefluxStop® and its potential to revolutionize anti-reflux treatment options.
Dr. Peter Forsell, Founder and CEO of Implantica, expressed gratitude towards the dedicated surgeons collecting clinical data on RefluxStop®. He highlighted that with approximately 73 million Americans suffering from GERD, the need for innovative solutions is critical. Dr. Forsell pointed out how the welcoming response from AFS attendees shows the treatment's potential to become the go-to solution for acid reflux.
As we align closer to the release of RefluxStop®, the anticipation from healthcare professionals signals a shift in how GERD might be treated. With its innovative framework and proven efficacy, RefluxStop® stands out as a burgeoning alternative in anti-reflux surgery.
About Implantica
Implantica is a MedTech group that develops advanced technologies to address medical concerns directly within the body. Their flagship product, RefluxStop®, is designed to prevent gastroesophageal reflux and is backed by successful clinical trials, illustrating its ability to reshape the anti-reflux treatment landscape. Alongside RefluxStop®, Implantica also explores eHealth solutions and has developed a pipeline of unique, patent-protected technologies that integrate remote monitoring and control that enhance patient care.
About RefluxStop®
RefluxStop® represents a significant advancement in the treatment of GERD and showcases innovation in surgical methods. Unlike traditional techniques that encircle the esophagus, leading to various post-operative complications, RefluxStop® offers a less invasive approach that maintains the integrity of the lower esophageal sphincter. The device restores natural positioning, aiding in the functionality of the body’s intrinsic anti-reflux capability.
Frequently Asked Questions
What is RefluxStop®?
RefluxStop® is an innovative medical device developed by Implantica for the treatment of acid reflux, designed to prevent gastroesophageal reflux.
Who attended the AFS meeting discussing RefluxStop®?
The AFS meeting saw attendance from over 600 medical professionals, including leading foregut surgeons and gastroenterologists eager to learn about RefluxStop®.
What makes RefluxStop® different from traditional treatments?
Unlike traditional anti-reflux surgeries that encircle the esophagus, RefluxStop® treats the issues of acid reflux while preserving the body’s natural anatomy, significantly reducing common side effects.
What is the potential market for RefluxStop® in the U.S.?
With around 73 million Americans suffering from acid reflux, there is a significant potential market for RefluxStop® as a preferred treatment option in the U.S.
Who is the CEO of Implantica?
The CEO of Implantica is Dr. Peter Forsell, who has been instrumental in guiding the company towards innovative medical solutions like RefluxStop®.
